Daily Archives: April 3, 2020

Representational Image

The latest study conducted by the team of international scientistsrevealed that the novel coronavirus could have transmitted from animals to humans years before the first case was detected in Wuhan, China.

The novel coronavirus, officially named SARS-CoV-2, has spread across more than 200 countries and territories across the globe. The infection COVID-19 has already claimed more than 43,000 lives since its outbreak back in December 2019 in Wuhan. Ever since the outbreak was reported, researchers have been trying to decode the origin of the novel coronavirus strain.

Origin of novel coronavirus

Using a comparative analysis of genomic datacollected from various genetic studies of the coronavirusan international team of researchers propose two possible hypotheses about the origin of this deadly virus.

Among the origin hypothesis, one theory suggests that novel coronavirus may have crossed from the animal barrier to settle in humansbefore it evolved into an active strain and started to induce the disease. It is possible that a progenitor of SARS-CoV-2 jumped into humans, acquiring the genomic features through adaptation during undetected human-to-human transmission, says the paper.

Another, far scarier scenario is that it evolved into the current strain in an animal host before transmission to humans. In this scenario, there is the risk of future re-emergence similar outbreaks, the study highlights.

The correspondence was published in Nature Medicine. The researchers compared the genetic code of the novel coronavirus from its ancestral strains, found in bats and pangolin, to understand the evolutionary history of the virus. The researchers from different institutes in the United States, Britain and Australia, also explain the notable features of the SARS-CoV-2 genome in this paper.

A bat or a pangolin?

In December end, when the suspicious cases of pneumonia emerged in Wuhan, it was linked to the Huanan Market in the province, which indicated the presence of an animal source for the spread of the virus.

Soon, an unknown strain of the virus was isolated by the team of researchers from the Wuhan Institute of Virology. The origin of the strain was traced to a bat virus found close to the China-Myanmar border. However, the bat coronavirus and the novel coronavirus strains were only 96 percent similarnot sufficient to attribute as the definite source. The bat virus did not showcase the presence of spike proteinrequired for the virus to bind in human cells.

The study also highlights the presence of the SARS-CoV-2-related coronavirus in the illegally imported Malayan pangolins. Further, the analyses showcased the presence of spike protein required to optimise the virus for transmission in humans among the coronaviruses found in pangolins.

However, the present study reveals that the novel coronavirus found responsible for the current outbreak had a mutation in its genes at the polybasic cleavage site, which was not found in both coronaviruses identified in bats and pangolins.

Evolution of coronavirus by natural selection

Analysing the research so far, the scientists say that the novel coronavirus had acquired both the polybasic cleavage site and mutations in the spike protein suitable for binding to humans naturally. The question, however, remains whether this natural selection occurred in humans or animals.

The spike protein interacts with furin, a widely distributed enzyme in the human body. This interaction mediates the fusion of virus and human cell membranes, which triggers the symptoms and makes it contagious. Some of the virus diseases like HIV and Ebola also have the furin-like cleavage site, which makes them contagious.

Moreover, the study also says an animal host to allow natural selection efficiently, there has to be a high population density. The dwindling population of pangolins is, therefore, may not be an ideal host for such a mutation to occur.

The study concludes that it is important to understand the properties of a virus to trace the origins of the pandemic. Scientists hope that a detailed understanding of how an animal virus-infected humans will help in the prevention of future zoonotic events.

Visit link:

Novel Coronavirus Could Have Entered and Evolved in Humans Much Before Outbreak in Wuhan: Study - The Weather Channel

Human evolution is characterized by several human species living on the same surface and interbreeding at the same time. This process has eventually led to our formation or at least that is the theory that anthropology presented. New research has been performed, and it is demonstrating that this common belief is an error.

Anthropology and archeology students were taught to follow the this evolutionary line of Homo sapiens, tracing their origins back in time through ancestral species and some other biases from biology. Nowadays, the scientists studying human evolution do not think that this is applicable anymore. They are stating that our origin is way more complicated than this narrative.

Today evidence that combats the theory has been released. Scientists are providing analysis that shows the existence of different other species that bear a resemblance to the human of todays society.

The research is militating for the importance of the exchange of fortuitous genetic material between these groups while finding the one species from which humans evolved is still challenging the researchers.

A skull that was initially assigned to the Homo rhodesiensis, and then to Homo heidelbergensis, was found in 1921 and reanalyzed during modern times by researchers. Homo heidelbergensis is a species that evolved 600.000 years ago and dating the skulls origin has been a significant burden for the scientists. Additionally, the revealed dating coincides with the debut of humans, which happened 300.000 years ago in the Middle Stone Age.

However, some researchers contradict the relevance of the Broken Hill skull in this study. Katerina Harvati is a paleoanthropologist at the Eberhard Harls University of Tubingen. She is stating that the skull does not deliver any particular feature that could link it to the evolution of modern humans. In addition to this, she believes that the Homo rhodesiensis and heidelbergensis are likely to be a late survival stage of the Homo sapiens.

Ethelene is the main editor on DualDove, she likes to write on the latest science news.

Read more:

Researchers Elaborated New Theories On The Human Evolution - Dual Dove

Lets start up with the current stock price of Sangamo Therapeutics, Inc. (SGMO), which is $6.77 to be very precise. The Stock rose vividly during the last session to $6.77 after opening rate of $6.08 while the lowest price it went was recorded $6.08 before closing at $6.21.

Sangamo Therapeutics, Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the companys stock is recorded $13.91 on 04/03/19, with the lowest value was $4.81 for the same time period, recorded on 03/17/20.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Sangamo Therapeutics, Inc. shares are logging -51.33% during the 52-week period from high price, and 40.75% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $4.81 and $13.91.

The companys shares, operating in the sector of healthcare managed to top a trading volume set approximately around 1.91 million for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Sangamo Therapeutics, Inc. (SGMO) recorded performance in the market was -19.12%, having the revenues showcasing -17.54% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 825.13M, as it employees total of 354 workers.

During the last month, 5 analysts gave the Sangamo Therapeutics, Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 2 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 8.17, with a change in the price was noted -2.57. In a similar fashion, Sangamo Therapeutics, Inc. posted a movement of -27.52% for the period of last 100 days, recording 2,166,324 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity. The total Debt to Equity ratio for SGMO is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

Raw Stochastic average of Sangamo Therapeutics, Inc. in the period of last 50 days is set at 44.75%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 48.16%. In the last 20 days, the companys Stochastic %K was 40.30% and its Stochastic %D was recorded 38.91%.

Bearing in mind the latest performance of Sangamo Therapeutics, Inc., several moving trends are noted. Year-to-date Price performance of the companys stock appears to be encouraging, given the fact the metric is recording -19.12%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -21.73%, alongside a downfall of -48.04% for the period of the last 12 months. The shares increased approximately by 14.41% in the 7-day charts and went up by 1.65% in the period of the last 30 days. Common stock shares were lifted by -17.54% during last recorded quarter.

Go here to see the original:

Sangamo Therapeutics, Inc. (SGMO) is primed for evolution with the beta value of 2.12 - The InvestChronicle

When Roselia was introduced in Generation III of Pokmon, it wouldn't have been known that it would eventually receive a pre-evolution Baby Pokmon and evolution in the following generation. But, Budew, the Baby form for Roselia, and new evolution, Roserade, both came on the scene in Generation IV.

RELATED:Pokmon: Every Grass Gym-Leader So Far, Ranked

Budew itself is a great Pokmon. It's cute, loveable, and has some interesting lore and facts attached to it. The Grass/Poison-type is modeled after a small rosebud, which will eventually grow into the rose-bearing Roselia. Here's an explanation on how to evolve this Baby Pokmon, and some other interesting things about it.

After catching Budew in the wild (in many different places across the games) or hatching it from an egg, it will need to evolve into Roselia before it's of any use in battle. In order to do this, you'll need to be nice to it and treat it well. This is because Budew evolves with a high friendship level.

Once it's friendly toward you, level it up in the daytime, and it will evolve into Roselia. From there, if you want to make this Pokmon even more powerful, you can evolve the Roselia into Roserade by exposing it to a Shiny Stone.

If you're already in possession of a Roselia or Roserade and want to fill Budew's Pokdex entry, you'll need to breed a female of one of them with either a Ditto or another compatible Pokmon. Eggs will hatch into the species that matches the mother (or non-Ditto Pokmon). However, there's a catch.

RELATED:Pokmon: Every Pokmon That Can Learn Petal Dance By Leveling Up

If you breed a Roselia or Roserade, the egg will hatch into a Roselia. In order to make it hatch into a Budew, one of the parents will need to hold a Rose Incense.

Like many Baby Pokmon, Budew is virtually useless in most battle scenarios. Its stats are a joke and its movepool is very bad. Interestingly, Budew will learn zero moves by leveling up.

It can have Absorb, Growth, Stun Spore, and Worry Seed at Level 1 or when hatched, but it will not learn any other moves if leveled all the way to 100. It can learn a fair few Egg moves or TM moves, but it will need to evolve to learn anything else.

According to the Pokdex, Budew can be very poisonous to humans if they get too close at the wrong time. Per its Pokdex entries, Budew likes to live near water and dispense pollen that causes sneezing and runny noses. Its pollen is described as "toxic" in some entries, and it can release poison into the air via this pollen.

You'll need to get friendly with your Budew to evolve it, but watch out for its toxic pollen release, because it won't be fun to deal with those sinus issues.

While you're doing your best to avoid Budew's poisonous pollen clouds, you'll want to make sure to stay very far away if it is consuming very clean water. This is because, according to the Pokdex, clean water makes it much more toxic and poisonous.

RELATED:Pokmon: Every Poison-Type Gym Leader, Ranked According To Difficulty

Considering wild Budew like to live near clean pools of water, chances are that most of them would be pretty poisonous if you get too close. As it evolves, it learns to harness this poisonous nature as well. Roserade is said to contain two deadly toxins, one in each hand, and it can jab powerfully with fatal results.

Most Pokmon have two or more abilities two regular abilities, and often a hidden ability. Budew, despite its uselessness in battle, has three abilities that are all really good. Its first ability, Natural Cure, heals all status conditions on the Pokmon when it is switched out. It will also heal any status condition when the battle finishes.

Its secondary ability, Poison Point, allows Budew a 30 percent chance to poison any Pokmon that makes contact with it. Its hidden ability, Leaf Guard, prevents Budew from being afflicted with non-volatile status conditions during harsh sunlight.

Like its evolutions, Budew has a really fantastic shiny form. It will swap its shade of green for a more yellow shade of it. The small foliage under its face will also change to a nice purple, which matches perfectly with its Poison-typing.

The two seeds inside its vines, which are normally red and blue to match its evolutions, will become purple and black, again, like its evolutions' roses. Overall, shiny Budew matches its typing and evolutionary family much better than regular Budew.

Speaking of the seeds inside its vines, it's a really great touch that they match Roselia and Roserade. These two beautiful Grass/Poison-types are adorned with two floral hands. Roselia has a blue rose and a red rose, one on each hand. Roserade's are the same shade of red and blue, but expanded to contain three flowers per hand.

RELATED:Pokmon: The 10 Best Gen III Pokmon In Sword & Shield

Budew's seeds, which are rarely seen as they're enclosed in its vines, are the same shades of red and blue. It's a perfect match and a subtle detail, but a great one.

It's rare, but there are occasionally Pokmon that are seen in the anime before the games. Some prominent examples are Misty's Togepi, Ho-oh, and Munchlax. Interestingly, Budew confused many when it was revealed in the anime, as it hadn't yet been seen anywhere before that.

In the episode, Dawn of a New Era!, Pochama VS Subomie! Hikari's First Battle!!, the fourth episode of the Diamond & Pearl arc, Ash and Dawn run into a trainer named Nando, who has a Budew. The Grass/Poison-type had not yet been revealed to the public, so Japanese viewers were very confused at the time.

Most Baby Pokmon (with very few exceptions) are introduced in a later generation than their evolved forms. This is true for Roselia, too, who was introduced the generation before Budew. Some Pokmon, like Magmar and Electabuzz, received Baby forms in one generation and then further evolutions later down the road.

Roselia is unique in this sense. The Baby form and evolution were both introduced in the same generation. This means that Budew and Roserade are the only Pokmon to be listed next to each other in the National Dex without their middle stage between them.

NEXT:The 5 Best Shiny Pokmon from Generation III (& The 5 Worst)

NextCall of Duty: 10 Things You Should Avoid Doing In Warzone If You Want To Survive

Michael is a journalist with several years of experience writing about video games, television, and social issues. He loves playing indie platformers, old games he's already finished ten times, and Pokemon. Michael also enjoys cold weather and drinking too much coffee.

More here:

How To Evolve Budew (& 9 Other Facts About The Pokmon) - TheGamer

In a few short weeks, COVID-19 has spread on an unprecedented scale, touching every corner of the globe and impacting all walks of life. In our industry we have seen automotive supply chains ground to a halt as manufacturers shut down plants in order to prevent the spread. Of course, we see annual shutdowns and even unplanned shutdowns in normal business, but we are now in unprecedented territory with factories shutting without notice and without any real knowledge of how long for. This means that when things return to normal we will be facing one of the biggest threats to supply chain resilience confusion.

Before a planned shutdown starts, the return to production and the increase back to full capacity is carefully considered before the plant closes. But with this shutdown initiated so quickly, businesses will need to be flexible and reactive when it comes to decisions on shift patterns and speed of return to capacity when production does recommence. The situation is so fluid that we dont know which markets will recover from a consumer demand point of view, and therefore which models vehicle manufacturers will need to make. We also have no idea, from a supply perspective, which countries will be able to restart production first. The supply chain will continue to shift and evolve as time passes and restrictions are lifted in each country. Evolution is constantly consulting with key customers to assess the impact of the sudden stop, identify existing gaps in supply and put in place plans to react quickly as customer demands change when production resumes.

The question will not only be are there enough parts to produce cars, but also will there be an availability of labour to fit those parts? Car dealerships are also seeing a substantial decline in demand, with reports of a drop of 22% in some areas hardest hit in the first half of March. While the shutdown is ongoing, manufacturers are having to review their order banks and forecasts, which will have implications deep in the supply chain. Focus will be on which areas are recovering quickest and capacity will be focused on supplying these regions.

Please click here to view the full press release.

SOURCE: Evolution Time Critical

More:

Evolution Time Critical: What does the next 3 months hold for automotive supply chains? - Automotive World

Freeport-McMoRan Inc. (FCX) is priced at $6.39 after the most recent trading session. At the very opening of the session, the stock price was $6.54 and reached a high price of $6.74, prior to closing the session it reached the value of $6.31. The stock touched a low price of $6.14.

Freeport-McMoRan Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the companys stock is recorded $14.68 on 04/17/19, with the lowest value was $4.82 for the same time period, recorded on 03/19/20.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Freeport-McMoRan Inc. shares are logging -56.46% during the 52-week period from high price, and 32.57% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $4.82 and $14.68.

The companys shares, operating in the sector of basic materials managed to top a trading volume set approximately around 31.28 million for the day, which was evidently higher, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Freeport-McMoRan Inc. (FCX) recorded performance in the market was -51.30%, having the revenues showcasing -51.59% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 10.45B, as it employees total of 27500 workers.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 10.92, with a change in the price was noted -4.88. In a similar fashion, Freeport-McMoRan Inc. posted a movement of -43.30% for the period of last 100 days, recording 26,881,076 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity. The total Debt to Equity ratio for FCX is recording 1.06 at the time of this writing. In addition, long term Debt to Equity ratio is set at 1.06.

Raw Stochastic average of Freeport-McMoRan Inc. in the period of last 50 days is set at 19.53%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 31.46%. In the last 20 days, the companys Stochastic %K was 30.86% and its Stochastic %D was recorded 28.72%.

If we look into the earlier routines of Freeport-McMoRan Inc., multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be encouraging, given the fact the metric is recording -51.30%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -27.96%, alongside a downfall of -51.44% for the period of the last 12 months. The shares increased approximately by 2.43% in the 7-day charts and went up by -8.58% in the period of the last 30 days. Common stock shares were lifted by -51.59% during last recorded quarter.

See the article here:

Freeport-McMoRan Inc. (FCX) is primed for evolution with the beta value of 2.22 - The InvestChronicle

Colony Capital, Inc. (CLNY) is priced at $1.56 after the most recent trading session. At the very opening of the session, the stock price was $1.57 and reached a high price of $1.72, prior to closing the session it reached the value of $1.56. The stock touched a low price of $1.52.

Colony Capital, Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the companys stock is recorded $6.14 on 09/30/19, with the lowest value was $1.33 for the same time period, recorded on 03/19/20.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Colony Capital, Inc. shares are logging -74.59% during the 52-week period from high price, and 17.29% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $1.33 and $6.14.

The companys shares, operating in the sector of financial managed to top a trading volume set approximately around 4.02 million for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Colony Capital, Inc. (CLNY) recorded performance in the market was -67.16%, having the revenues showcasing -66.74% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 821.95M, as it employees total of 400 workers.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 4.2178, with a change in the price was noted -3.9200. In a similar fashion, Colony Capital, Inc. posted a movement of -71.53% for the period of last 100 days, recording 3,689,219 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity. The total Debt to Equity ratio for CLNY is recording 2.23 at the time of this writing. In addition, long term Debt to Equity ratio is set at 2.23.

Raw Stochastic average of Colony Capital, Inc. in the period of last 50 days is set at 5.99%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 8.61%. In the last 20 days, the companys Stochastic %K was 10.45% and its Stochastic %D was recorded 14.40%.

Lets take a glance in the erstwhile performances of Colony Capital, Inc., multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be encouraging, given the fact the metric is recording -67.16%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -72.63%, alongside a downfall of -71.84% for the period of the last 12 months. The shares increased approximately by 1.43% in the 7-day charts and went up by -35.00% in the period of the last 30 days. Common stock shares were lifted by -66.74% during last recorded quarter.

Continued here:

Colony Capital, Inc. (CLNY) is primed for evolution with the beta value of 1.59 - The InvestChronicle

Crown Holdings, Inc. (CCK) is priced at $55.00 after the most recent trading session. At the very opening of the session, the stock price was $55.06 and reached a high price of $57.5, prior to closing the session it reached the value of $55.10. The stock touched a low price of $53.71.

Crown Holdings, Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the companys stock is recorded $80.57 on 02/14/20, with the lowest value was $42.97 for the same time period, recorded on 03/23/20.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Crown Holdings, Inc. shares are logging -31.73% during the 52-week period from high price, and 28.00% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $42.97 and $80.57.

The companys shares, operating in the sector of consumer goods managed to top a trading volume set approximately around 1.52 million for the day, which was evidently higher, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Crown Holdings, Inc. (CCK) recorded performance in the market was -24.18%, having the revenues showcasing -23.83% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 7.57B, as it employees total of 33000 workers.

During the last month, 8 analysts gave the Crown Holdings, Inc. a BUY rating, 1 of the polled analysts branded the stock as an OVERWEIGHT, 3 analysts were recommending to HOLD this stock, 1 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 70.86, with a change in the price was noted -19.30. In a similar fashion, Crown Holdings, Inc. posted a movement of -25.98% for the period of last 100 days, recording 1,300,125 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity. The total Debt to Equity ratio for CCK is recording 4.65 at the time of this writing. In addition, long term Debt to Equity ratio is set at 4.57.

Raw Stochastic average of Crown Holdings, Inc. in the period of last 50 days is set at 32.00%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 39.79%. In the last 20 days, the companys Stochastic %K was 40.50% and its Stochastic %D was recorded 42.40%.

If we look into the earlier routines of Crown Holdings, Inc., multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be encouraging, given the fact the metric is recording -24.18%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -11.13%, alongside a downfall of -0.60% for the period of the last 12 months. The shares increased approximately by 2.22% in the 7-day charts and went up by -5.27% in the period of the last 30 days. Common stock shares were lifted by -23.83% during last recorded quarter.

Excerpt from:

Crown Holdings, Inc. (CCK) is primed for evolution with the beta value of 1.36 - The InvestChronicle